

# Timucin Kasifoglu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8399523/publications.pdf>

Version: 2024-02-01

22  
papers

523  
citations

933447

10  
h-index

752698

20  
g-index

22  
all docs

22  
docs citations

22  
times ranked

739  
citing authors

#	ARTICLE	IF	CITATIONS
1	Familial Mediterranean fever: An updated review. <i>European Journal of Rheumatology</i> , 2014, 1, 21-33.	0.6	129
2	Amyloidosis and its related factors in Turkish patients with familial Mediterranean fever: a multicentre study. <i>Rheumatology</i> , 2014, 53, 741-745.	1.9	96
3	Familial Mediterranean fever is associated with a wide spectrum of inflammatory disorders: results from a large cohort study. <i>Rheumatology International</i> , 2020, 40, 41-48.	3.0	45
4	Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2015, 42, 1661-1666.	2.0	43
5	Frequency of Abdominal Surgery in Patients with Familial Mediterranean Fever. <i>Internal Medicine</i> , 2009, 48, 523-526.	0.7	28
6	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021, 108, 84-99.	6.2	26
7	Comparison of early versus late onset familial Mediterranean fever. <i>International Journal of Rheumatic Diseases</i> , 2018, 21, 880-884.	1.9	25
8	Budd-Chiari syndrome in the course of Behcet's disease: Clinical and laboratory analysis of four cases. <i>Joint Bone Spine</i> , 2007, 74, 245-248.	1.6	24
9	The distribution of MEFV mutations in Turkish FMF patients: multicenter study representing results of Anatolia. <i>Turkish Journal of Medical Sciences</i> , 2019, 49, 472-477.	0.9	23
10	Predictors of persistent inflammation in familial Mediterranean fever and association with damage. <i>Rheumatology</i> , 2021, 60, 333-339.	1.9	21
11	Colchicine intolerance in FMF patients and primary obstacles for optimal dosing. <i>Turkish Journal of Medical Sciences</i> , 2020, 50, 1337-1343.	0.9	13
12	Exon 2: Is it the good police in familial mediterranean fever?. <i>European Journal of Rheumatology</i> , 2019, 6, 33-36.	0.6	10
13	Different disease subtypes with distinct clinical expression in familial Mediterranean fever: results of a cluster analysis. <i>Rheumatology</i> , 2016, 55, 343-346.	1.9	8
14	Methodology of a new inflammatory arthritis registry: TReasure. <i>Turkish Journal of Medical Sciences</i> , 2018, 48, 856-861.	0.9	7
15	Budd-Chiari syndrome in Behçet's disease: a retrospective multicenter study. <i>Clinical Rheumatology</i> , 2021, , 1.	2.2	7
16	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1615-1623.	0.9	6
17	The Long-Term Outcomes for Patients with Budd-Chiari Syndrome Caused by Behçet's Disease: A Case Series on the Results, from Cirrhosis to Death. <i>Hepatitis Monthly</i> , 2016, 16, e32457.	0.2	4
18	Comparison of clinical features in FMF patients according to severity scores: An analysis with the ISSF scoring system. <i>European Journal of Rheumatology</i> , 2020, 7, 68-70.	0.6	3

#	ARTICLE	IF	CITATIONS
19	Factors associated with damage in patients with familial Mediterranean fever. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 42-48.	0.8	2
20	Appendectomy history is associated with severe disease and colchicine resistance in adult familial Mediterranean fever patients. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1706-1711.	0.9	1
21	Phenotypic characterisation of Familial Mediterranean Fever patients harboring variants of uncertain significance. <i>Turkish Journal of Medical Sciences</i> , 2021, 51, 1695-1701.	0.9	1
22	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. <i>Rheumatology International</i> , 2021, 41, 1915-1924.	3.0	1